Govt schools prepare for dist leg of national children's sc exhibition
The theme, 'Science and Technology for Sustainable Future', aims to encourage children to explore scientific solutions to real-world challenges in a sustainable manner. It is divided into several sub-themes, including food, health and hygiene, transport and communication, natural farming, disaster management, mathematical modeling and computational thinking, waste management and resource management to ensure diverse and in-depth exploration.
District education officer Vinay Kumar said, "Science teachers in schools across the state have been given the responsibility to identify, guide, and support the students in developing innovative exhibits aligned with the themes. Internal school-level exhibitions must be conducted in a timely manner to select the best project for district-level submission."
Selected entries from each school are to be submitted to the office of the district education officer (DEO) by July 30 at either deoranchiscience@gmail.com or rmsranchi0651@gmail.com.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
새로 나온 '실손보험' 최적가 비교가입! "월 보험료 낮추고, 보장은 든든하게 챙기세요"...
굿리치 [등록번호:제2006038313호]
가격 받기
Undo
School authorities and students are advised to visit the NCERT website, www.ncert.nic.in, for further clarity and guidelines on exhibit preparation and selection processes.
The event is sponsored by the National Council of Educational Research and Training (NCERT), New Delhi.
Ranchi: Govt school teachers across the state are identifying and nominating students enrolled in Classes VI to XII for the district leg of the national-level 52nd National Children's Science Exhibition-2025.
The theme, 'Science and Technology for Sustainable Future', aims to encourage children to explore scientific solutions to real-world challenges in a sustainable manner. It is divided into several sub-themes, including food, health and hygiene, transport and communication, natural farming, disaster management, mathematical modeling and computational thinking, waste management and resource management to ensure diverse and in-depth exploration.
District education officer Vinay Kumar said, "Science teachers in schools across the state have been given the responsibility to identify, guide, and support the students in developing innovative exhibits aligned with the themes. Internal school-level exhibitions must be conducted in a timely manner to select the best project for district-level submission."
Selected entries from each school are to be submitted to the office of the district education officer (DEO) by July 30 at either deoranchiscience@gmail.com or rmsranchi0651@gmail.com. School authorities and students are advised to visit the NCERT website, www.ncert.nic.in, for further clarity and guidelines on exhibit preparation and selection processes.
The event is sponsored by the National Council of Educational Research and Training (NCERT), New Delhi.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
5 hours ago
- Time of India
JNVU odd semester PG results for M.Sc and MA 2024-25 announced at jnvuiums.in
JNVU announces and MA odd semester results for 2024-25 at JNVU odd semester PG result 2025: Jai Narain Vyas University (JNVU), Jodhpur, has officially declared the odd semester examination results for the academic year 2024-25. The results for postgraduate courses in and MA programmes under the NEP 2020 curriculum are now available online. Students who appeared for the first and third semester examinations can access their results via the official university examination portal, The university's announcement covers results for various subjects including Botany, Philosophy, and English. The released results aim to provide students with their academic performance updates for the ongoing semester, assisting them in planning their future academic and professional paths. Post graduation results now live for multiple courses JNVU has published the results for several postgraduate semesters. The details include (Semester) NEP 2020 Ist Semester Botany examination result, (Semester) NEP 2020 IIIrd Semester Botany examination result, MA (Semester) NEP 2020 IIIrd Semester Philosophy examination result, and MA (Semester) NEP 2020 Ist Semester English examination result. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Providers are furious: Internet access without a subscription! Techno Mag Learn More Undo All results were made available on July 5, 2025. Students enrolled in these courses are advised to verify their results at the earliest to avoid any discrepancies. The university has ensured that the results are accessible and user-friendly on their examination management system website, allowing smooth retrieval of academic records. How to download JNVU odd semester PG results at To facilitate students in accessing their results, here are the steps to download the JNVU odd semester results from the official portal: Step 1: Visit the official examination website at Step 2: Look for the link titled 'Odd Semester Examination Results 2024-25' on the homepage. Step 3: Click on the relevant course and semester result link (e.g., Botany Ist Sem, MA Philosophy IIIrd Sem). Step 4: Enter your roll number or registration details as required. Step 5: Submit the information to view your results, and download or print the mark sheet for future reference. JNVU's official website continues to serve as the primary platform for updates related to examination schedules, results, and academic notifications. Students experiencing technical difficulties or discrepancies in their results are encouraged to contact the university's examination department promptly. The university remains committed to transparent and timely dissemination of academic outcomes to support student progress and maintain academic integrity in the ongoing session. TOI Education is on WhatsApp now. Follow us here . Ready to navigate global policies? Secure your overseas future. Get expert guidance now!
Time of India
5 hours ago
- Time of India
Anthem Biosciences IPO: Rs 3,395 crore IPO to open on July 14
The initial public offering (IPO) of Anthem Biosciences will open for subscription on Monday, July 14. The Bengaluru-based CRDMO player is planning to raise Rs 3,395 crore through the issue. The issue will conclude on Wednesday, July 16. About Anthem Biosciences IPO The IPO is an Offer for Sale (OFS) and comprises stake sale aggregating up to Rs 350 crores each by Ganesh Sambasivam and K Ravindra Chandrappa who are promoter selling shareholders. Up to Rs 1,325 crores will be offloaded by Viridity Tone LLP and up to Rs 320 crores by Portsmouth Technologies LLC (Investor Selling Shareholders). by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Free P2,000 GCash eGift UnionBank Credit Card Apply Now Undo It also includes stake sales of Rs 320 crores each by Malay J Barua, Rupesh N Kinekar and Satish Sharma, up to Rs 80 crore by Prakash Kariabettan and up to Rs 10 crore by K Ramakrishnan. About Anthem Biosciences Anthem's business comprises Contract Research, Development and Manufacturing Organization (CRDMO) services and the manufacture and sale of specialty ingredients. It offers a comprehensive, integrated and highly customizable range of CRDMO services across the New Chemical Entity (NCE) and New Biological Entity (NBE) lifecycles. The company claims to have a strong presence across various modalities, such as RNAi, ADC, peptides, lipids and oligonucleotides, and manufacturing techniques, such as flow chemistry, enzymatic processes, biocatalysis and fermentation, offering a broad range of technology capabilities for drug development. It also manufactures and sells complex specialized fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars. Live Events Ajay Bhardwaj (Chairman, MD & CEO), Ganesh Sambasivam (Whole-time Director and Chief Scientific Officer), K Ravindra Chandrappa (Whole-time Director and Chief Operating Officer) and Ishaan Bhardwaj (Vice President) are the Promoters of the company. The company, which was incorporated in 2006, has two operational manufacturing facilities in India, Unit I (Bommassandra) and Unit II (Harohalli), both in Karnataka, with an aggregate annual custom synthesis capacity of 270 kL and fermentation capacity of 142 kL, as of March 31, 2025. According to the RHP, the company is in the process of expanding its custom synthesis capacity at Unit II (Harohalli) by 130 kL as well as expanding its custom synthesis capacity by 25kL and fermentation capacity by 40kL by constructing Unit III (Neoanthem Lifesciences Private Limited, wholly-owned Subsidiary), both expected to be fully operational by the first half of Fiscal 2026. Post-expansion activities, the aggregate annual custom synthesis capacity and fermentation capacity is expected to increase to 425 kL and 182 kL, respectively. The fermentation capacity of 182 kL is expected to be more than six times the capacity of the second largest player in this industry, according to the F&S Report. Anthem Biosciences financials Its revenue from operations increased by 30% to Rs 1,844 crores in FY25 from Rs 1,419 crores in FY24. The PAT for the year ended March 31, 2025 was Rs 451 crores, a jump of 22.86% over FY24. Sai Life Sciences Limited, Syngene International Limited , Cohance Lifesciences Limited , (Formerly Suven Pharmaceuticals) and Divi's Laboratories Limited are the listed peers of Anthem Biosciences, as per its RHP. Anthem Biosciences lead managers The Book Running Lead Managers to the offer are JM Financial Limited , Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited and Nomura Financial Advisory and Securities (India) Private Limited. The equity shares are proposed to be listed on BSE and NSE.
Time of India
8 hours ago
- Time of India
PGI leads phase 1 clinical trials for indigenous cancer drug development in India
Chandigarh: The PGI is at the forefront of India's efforts to develop indigenous solid tumour cancer drugs, serving as one of the four pivotal Phase 1 Human Clinical Trial Units (CTUs) established by the Indian Council of Medical Research (ICMR). This initiative marks a significant leap in fostering innovation and promoting homegrown research in the country's pharmaceutical landscape. The molecule for the cancer drug is undergoing phase 1 clinical trials in PGI. The ICMR's visionary plan to create a nationwide network of CTUs aims to bolster the evaluation of new devices, diagnostics, and drugs in their crucial early phases of development. "PGI has been one of the four such units for phase one clinical trials in the country. For new medicine used in humans for the first time, Phase 1 assesses safety. Earlier, these studies were mainly done by big companies, but now ICMR is supporting indigenous clinical trials," stated Dr. Rajiv Bahl, director of ICMR. The ICMR director informed that phase 1 clinical trials elsewhere in these CTUs are ongoing for the development of Zika virus and antiflu vaccines. Alongside PGI, the other three distinguished CTUs in this Phase 1 network are KEM Mumbai, the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) Mumbai, and SRM Chennai. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like The Amount Kate Garraway's Husband Left Behind Will Shock You Weight Loss Groove Undo These institutions are integral to nurturing homegrown innovations, a key focus for the ICMR. Dr. Bahl said, "There are 75 such networks in the country for Phase 2 and Phase 3 clinical trials." PGI boasts a rich history in clinical drug trials, conducting the country's first human study in 2006. This pioneering trial involved an antimalarial drug molecule developed by the Central Drug Research Institute, Lucknow, with PGI playing a crucial role in developing a joint protocol and taking the research forward. Also, last year the PGI's CTU proposed an 8-bedded facility for the participating volunteers to be enhanced from the existing 4 beds. However, this facility has yet to take off. "One can compete with world-class innovations if there are better facilities for the volunteers who are the backbone of such clinical trials," said an official at the ICMR.
